PMID: 2498607Jan 1, 1989Paper

The use of difluoromethylornithine in congenital trypanosomiasis due to Trypanosoma brucei-gambiense

Médecine tropicale : revue du Corps de santé colonial
J PepinP J Schechter

Abstract

The authors describe their experience with two cases of congenital Trypanosoma brucei-gambiense trypanosomiasis treated with orally administered difluoromethylornithine. The first case tolerated well his treatment (35 days of DFMO) and has probably been definitively cured. The second case, already in a desperate condition upon admission, died after only 4 days of difluoromethylornithine (DFMO). The authors hypothesize that difluoromethylornithine (DFMO) may be the drug of choice for congenital trypanosomiasis because of its good absorption by the oral route, its ability to penetrate the cerebrospinal fluid especially in presence of meningeal inflammation and its activity against Trypanosoma brucei-gambiense.

Related Concepts

Related Feeds

African Trypanosomiasis

African trypanosomiasis, also known as sleeping sickness, is an insect-borne parasitic disease of humans and other animals. It is caused by protozoa of the species Trypanosoma brucei and almost invariably progresses to death unless treated. Discover the latest research on African trypanosomiasis here.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Related Papers

Médecine tropicale : revue du Corps de santé colonial
J PepinC Guern
Transactions of the Royal Society of Tropical Medicine and Hygiene
Prashant P JoshiPhilippe Truc
The British Veterinary Journal
G I Jibike, S M Anika
Bulletin de la Société de pathologie exotique et de ses filiales
G L KazyumbaN Nkanga
© 2022 Meta ULC. All rights reserved